Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›Samsung Asset Management›476070

476070

SAMSUNG Kodex Global Obesity Treatment TOP2 Plus ETF

Passive ETF Equity ESG Theme: Tomorrow's Treatments

Not rated

The 476070 Exchange Traded Fund (ETF) is provided by Samsung Asset Management. It is built to track an index: iSelect Global Obesity Treatment TOP2 Plus Index. This share class generates a stream of income by distributing dividends.

₩10,515

+₩85 (+0.81%) today

12:00 AM 09/17/26 Closed

1D price range

₩10,435₩10,545

52W price range

₩9,085₩12,785

YTD Perf.

-9.54%

YTD Flows

Annualized volatility

Fund AuM

€18M

Share class AuM

€18M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

KR7476070008

TER

0.45%

Inception date

2/14/2024

Issuer

Samsung Asset Management

Benchmark

iSelect Global Obesity Treatment TOP2 Plus Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
476310 RISE Global Obesity Care Industry TOP2+ ETF	+0.18%
PPH VanEck Pharmaceutical ETF	+0.33%
WELL Harbor Health Care UCITS ETF	-1.43%
CIB0 Vaneck Bionic Engineering Ucits ETF	+2.05%
GNOG Global X Genomics & Biotechnology UCITS ETF	+1.20%
AAKG ARK Genomic Revolution UCITS ETF	+3.07%
WDNA WisdomTree BioRevolution UCITS ETF	-0.45%
HMMJ Global X Marijuana Life Sciences Index ETF	-0.32%
BTECH Fineco AM MarketVector Bioproduction Tech & Tools ESG UCITS ETF	+4.16%
BIGT L&G Pharma Breakthrough UCITS ETF	-2.67%
XDNA iShares Genomics Immunology and Healthcare Index ETF	+1.53%
1ARKG Leverage Shares 1x ARK Genomic Tracker ETP	+3.32%

API

PerformanceDec 30, 2025 - Sep 16, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 07/31/26

Healthcare

98.96%

Unavailable

1.04%

Latest 476070 news

No content available for this fund

FAQ about 476070

476070 is a Passive ETF. This ETF provides exposure to Other Developed markets Equities.

476070 tracks the iSelect Global Obesity Treatment TOP2 Plus Index - USD, through a replication method.

476070 carries a total expense ratio (TER) of 0.45%, indicating the annual cost for holding the fund.

476070 was introduced to the market on February 14, 2024. It trades on South Korea

SAMSUNG Kodex Global Obesity Treatment TOP2 Plus ETF, 476070, is provided by Samsung Asset Management. Learn more about Samsung Asset Management here.

476070 oversees €18M in assets as of September 16, 2026.

476070 follows a distributing dividend policy, meaning it pays out income to investors. As of September 16, 2026, its 12-month trailing yield was 1.47%.

As of July 31, 2026, 476070 has significant geographic allocations in USA, Denmark and Switzerland.

As of July 31, 2026, 476070 focuses largely on Healthcare.

As of July 31, 2026, 476070 holds 10 positions in its portfolio, with 98.96% of assets concentrated in its top 15 holdings.

As of July 31, 2026, 476070 top three holdings include Novo Nordisk A/S, Eli Lilly & Co. and Rhythm Pharmaceuticals, Inc..

The base currency of 476070 is KRW.

Top 10 holdings

Data as of 07/31/26

Novo Nordisk A/S

26.84%

Eli Lilly & Co.

22.63%

Rhythm Pharmaceuticals, Inc.

6.87%

Regeneron Pharmaceuticals, Inc.

6.83%

Viking Therapeutics, Inc.

6.64%

Amgen, Inc.

6.39%

Roche Holding AG

6.02%

Zealand Pharma A/S

5.98%

Pfizer Inc.

5.42%

AstraZeneca PLC

5.33%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

SAMSUNG Kodex Global Obesity Treatment TOP2 Plus ETF

FAQ about 476070

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US